DataJoint has closed a $4.9M Seed funding round, co-led by Nina Capital, Inoca Capital Partners, and Capital Factory. The funding will fuel the growth of its team, expand its AI-powered SaaS platform, and extend its reach into life sciences and pharma industries across the U.S. and Europe.
Already used by over 100 labs, including Johns Hopkins and Harvard, DataJoint’s platform harmonizes multimodal data and streamlines workflows. The company’s participation in the PharmStars accelerator further highlights its role as a key innovator in digital health and pharma collaboration.
“This investment enables us to scale and bring transformative solutions to researchers and organizations,” said CEO Jim Olson.
With its cutting-edge AI integration, DataJoint is set to revolutionize data management in life sciences.